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Article
Analysis of phase II methodologies
for single-arm clinical trials with
multiple endpoints in rare cancers:
An example in Ewing’s sarcoma
P Dutton,1,2 SB Love,1,2 L Billingham3 and AB Hassan2,4
Abstract
Trials run in either rare diseases, such as rare cancers, or rare sub-populations of common diseases are challenging in
terms of identifying, recruiting and treating sufficient patients in a sensible period. Treatments for rare diseases are often
designed for other disease areas and then later proposed as possible treatments for the rare disease after initial phase I
testing is complete. To ensure the trial is in the best interests of the patient participants, frequent interim analyses are
needed to force the trial to stop promptly if the treatment is futile or toxic. These non-definitive phase II trials should
also be stopped for efficacy to accelerate research progress if the treatment proves to be particularly promising. In this
paper, we review frequentist and Bayesian methods that have been adapted to incorporate two binary endpoints and
frequent interim analyses. The Eurosarc Trial of Linsitinib in advanced Ewing Sarcoma (LINES) is used as a motivating
example and provides a suitable platform to compare these approaches. The Bayesian approach provides greater design
flexibility, but does not provide additional value over the frequentist approaches in a single trial setting when the prior is
non-informative. However, Bayesian designs are able to borrow from any previous experience, using prior information to
improve efficiency.
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1 Introduction
One of the biggest challenges for clinical trials for rare diseases and rare subsets of common diseases is patient
recruitment.1 When the patient population is very small, it is often not feasible to run a traditional fully powered
phase II trial in a reasonable time frame and it is impossible to repeat this in a phase III conﬁrmatory setting.
Likewise, as the population of candidates is so small, running a trial with a small chance of success (based on the
trial data so far) hinders research by consuming patients who would provide more useful information if they were
recruited to more promising trials that aimed to answer more decisive questions.
Research is increasingly focusing on personalised medicine, which is the customisation of treatment often using
genetics as a prognosis tool for treatments. For example, in cancer, the activity and clinical beneﬁt of several
agents mechanistically depend on speciﬁc mutations in genes that drive the cancer.2 Even in a given histological
subtype of a more common disease, some treatments may only work in a sub-population due to interactions
between a patient’s genes and treatment. It may therefore not be economical to treat all patients with a drug if
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there is no beneﬁt for those without a speciﬁc biomarker that is correlated with response. The general problems
that research into rare diseases faces are also relevant for research into the treatment of small sub-populations of
more common diseases.
Drugs are not often developed for rare diseases as it is historically more proﬁtable to target common diseases.
Academic research questions often ﬁll this gap, focusing on rare diseases and subtypes identiﬁed through
mechanistic studies, hypothesis testing and translational research. This research can and should inform the
clinical trial question, and may also enhance the potential impact of success at the clinical trial stage.
Separation of mechanistic research and clinical trials is deemed a weakness in the development strategies of
larger pharmaceutical companies.3 As early phase dose ﬁnding studies are often performed with patients in a
more common (or general) disease setting, interactions between the treatment and rare disease may not be well
understood. It is therefore important to have careful management of toxicity built into the design of a trial which
relies on such phase I trials but in an untested rare cancer setting. The most robust approach is to formally
consider the toxic event rate as a co-primary endpoint alongside patient response and to allow for stopping at
interim analyses if the observed toxicity rate is too high. Data safety monitoring committees (DSMC) are entrusted
with the role of ensuring trials only continue if they are in the interest of patients in the clinical trial setting.
However, DSMCs tend to have limited experience in rare disease settings, so need additional guidance on
acceptable toxicity rates.
We review a number of frequentist and Bayesian methods that have been adapted to incorporate two binary
endpoints and frequent interim analyses. The LINES trial is used as a motivating example and provides a suitable
platform to compare these approaches.
2 Methods
The question we set out to address concerns optimising the trial design for a phase II trial in this setting of rare
selected patient groups with co-primary endpoints: eﬃcacy and toxicity. We consider the following criteria to be
critical to this question from the clinical trial perspective:
. Small maximum sample size to ensure that answers can be obtained in a reasonable period
. Formal ability to stop the trial early if the treatment is ineﬀective
. Formal ability to stop the trial early if the treatment is toxic
. Formal ability to stop the trial early if the treatment is eﬀective
. Small expected sample size if the treatment is ineﬀective, toxic or both
. Controlled type I error for both futility and toxicity
. Reasonable power to observe eﬃcacy, provided the toxicity is acceptable
For the purpose of this paper, a patient will either respond or not respond to treatment and a patient will also
either experience or not experience a toxic event, both of which are binary endpoints. Let R be the probability of a





where R0 is some uninteresting probability of response. The alternative hypothesis is traditionally given a clinically




0 ), whereby if the probability of response was at least this large the investigators
would certainly be interested in investigating the treatment further. Under the frequentist approach, we wish the
type I error to be less than  (the probability that further research is recommended when the true response rate is at
most R0 ) and the type II error to be less than  (the probability that further research is rejected when the true
response rate is at least R1 ). Thus the power must be at least 1 .
If we include toxicity in the trial design, letting T be the probability of a patient experiencing a toxic event, the
hypotheses become
H0 : 
R5 R0 or 
T4 T0
H1 : 
R4 R0 and 
T5 T0
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Thus both high eﬃcacy and low toxicity are needed to recommend further research.
Frequentist methods are based on simulations that assume the null and alternative hypotheses are true.
The type I and type II errors encapsulate the likelihood of a given design giving the wrong result, if the null or
alternative hypotheses are true. In addition to this the expected sample size given a scenario is also a frequentist
property. The type I error can also be considered with respect to just one endpoint allowing more direct
comparisons between single endpoint designs and multi-endpoint designs.
Bayesian methods are based on current information, which is captured in a posterior distribution that
incorporates any prior knowledge with currently observed trial data. We denote the posterior distribution of
response and toxicity as R and T. Within the trial, commonly used Bayesian properties for this problem are
the following posterior probabilities: P T  T0 jdata, prior
 
, PðT  T1 jdata, priorÞ, P R  R0 jdata, prior
 
and PðR  R1 jdata, priorÞ. These correspond to no toxicity, toxicity, eﬃcacy and futility.
The interpretation of these properties is as follows:
. Type I error: The probability of rejecting the null hypothesis (H0) when it is true, or the largest probability of
rejecting H0 under the three null hypothesis scenarios, ðR0 , T0 Þ, (R0 , T1 ) and ðR1 , T0 Þ.
. Type II error: The probability of rejecting the alternative hypothesis (H1) when it is true.
. Expected sample size under a speciﬁc scenario: The expected sample size by simulation, given the
probabilities ðR, TÞ.
. Bayesian posterior probabilistic properties: The probability that the true value is in a speciﬁc range, based on all
known information (current data and prior information incorporated into the posterior distribution). For each
endpoint there are two values: the posterior probability of being superior to the null hypothesis (e.g. R0 Þ, and
the posterior probability of being inferior to the level assigned to the alternative hypothesis (e.g. R1 ).
Having two endpoints may increase the sample size required to achieve the same type I and II errors. To control
for type I and type II errors in a two-endpoint setting, the data must be considered under four scenarios: type I
error for the probability pairs ðR0 , T0 Þ, (R0 , T1 ) and ðR1 , T0 Þ, and type II error for the probability pair ðR1 , T1 Þ.
It is easy to see that the type I error for the ﬁrst pair is always smaller than the type I error for the second and third
pairs. It may also be useful to know the type I and type II errors under the assumption that there is no toxicity.
This is directly synonymous with the single-endpoint trial, and is a good way of examining the eﬀect of the second
endpoint on the design characteristics.
There are a number of both frequentist and Bayesian approaches to the problem of a single-arm two-endpoint
phase II trial in this setting. We evaluate two frequentist and three Bayesian approaches which allow two endpoint
designs. We discuss the frequentist and Bayesian properties of each method, so that they can be directly compared.
These methods are compared on the LINES trial, a phase II trial in Ewing’s sarcoma patients with relapsed or
metastatic disease.
3 Trial designs
The response and toxicity endpoints are binary. The data will come from a binomialðn, RÞ distribution for the
response endpoint and a binomialðn, TÞ distribution for the toxicity endpoint. The endpoints will be considered
independent from each other. The response endpoint can be discussed in terms of futility, when the response is
insuﬃcient, and in terms of eﬃcacy, when the response is suﬃcient. The treatment must be seen to be both
eﬃcacious and non-toxic in order to recommend further research at each analysis.
4 Frequentist approaches
4.1 Single-stage
The single-stage, single-endpoint frequentist trial is the oldest tried-and-tested trial design. There is no formal
interim analysis. Adjustments to the sample size can be made to formalise the intention to test two endpoints at the
same time.
4.2 Bryant and Day’s adaptation of Simon’s two-stage design
Simon’s two-stage design is one of the most inﬂuential frequentist designs: it is one of the ﬁrst trial designs to
actively look at a binary endpoint (response) for a trial at an interim analysis. Simon computed exact sample sizes
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for a two-stage design that could stop for futility at interim. Fleming4 had previously computed sample sizes for
this design using Gaussian asymptotics. Simon’s method reduces the expected sample size when the treatment of
interest is insuﬃciently eﬃcacious. Simon proposed two methods of optimisation, optimal design, which minimises
the expected sample size under the null hypothesis (H0), and minmax, which minimises the maximum sample size.
Simon noted that it is preferable to cease recruitment once the required number of patients for the interim analysis
have been recruited. The interim analysis thus has the required number of patients and has the properties of the
designed trial. The properties will diﬀer if recruitment is not stopped.
Simon’s two-stage design5 set the groundwork for a number of papers extending his design. Bryant and Day6
proposed including toxicity as a co-primary endpoint, which incorporated toxicity into Simon’s two-stage design.
Their approach allows stopping at interim analysis for toxicity or futility. They showed that error rates were
controlled even when the assumption of independence between the two endpoints was relaxed.
Further work on multiple endpoints was done by Conway and Petroni.7,8 They allowed for a trade-oﬀ between
response and toxicity.
4.3 Lan-Demets alpha spending approach
The Lan-Demets alpha spending approach9 is a generalised approach to multiple interim analysis for frequentist
designs. It allows more of the type I and/or type II error to be spent at later interim analyses using an alpha
spending function, such as the O’Brien–Fleming10 alpha spending function. This adjustment inﬂates the type I
error slightly, but much less than testing repeatedly at the full type I error level alpha. As no work has been
published on extending this methodology to multiple endpoints, it has not been included.
5 Bayesian methodology
The data are modelled using independent binomials. The beta distribution makes an ideal prior as it is conjugate.
The posterior is thus also a beta distribution
Rprior  BetaðR,RÞ
XR  Binomialðn,RÞ
Rposterior  BetaðR þ xR,R þ n xRÞ
Tprior  BetaðT,TÞ
XT  Binomialðn, TÞ
Tposterior  BetaðT þ xT,T þ n xTÞ
Prior knowledge can be incorporated into the model. This information is often collected via careful prior
elicitation meetings between relevant experts. Data from previous studies may be included if relevant, and may
be weighted depending on their relevance and quality.11 Non-informative priors can be used if no prior
information is available. Sensitivity analyses should be performed after concluding a trial that uses informative
prior information, to check that the conclusions are robust and that any signiﬁcant results are not solely created by
the prior information.
There are three possible outcomes at each interim analysis: stop for futility and/or toxicity, stop for eﬃcacy and
no toxicity or continue to recruit patients. The design must be ﬁnalised before recruiting any patients, and is used
as a guide during the trial. Although the Bayesian paradigm does not require interim analyses to occur at an exact
number of patients, the frequentist properties of the design are aﬀected by the number of patients at each interim
analysis.
An alternative modelling approach considers using a Dirichlet prior with multinomial data (two-by-two
outcomes for response and toxicity).12 This approach allows the dependence between response and toxicity to
be added, which is particularly important when the two endpoints are suspected to be dependent as it allows
dependent priors to be used. The adaptation is not required when independent priors are chosen.
Whitehead et al.13 proposed a Bayesian approach to compute sample size that can be considered a direct
translation of the frequentist approach to the Bayesian setting. They considered the posterior probabilities
PðR  R0 j data, priorÞ for eﬃcacy and ðR  R1 j data, priorÞ for futility. They proposed that the evidence
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be considered convincing if the probabilities were suﬃciently large. As a trial should be conclusive when stopped,
the sample size n is computed such that there exists xRC which satisﬁes
PðR  R0 jn,XR ¼ xR, priorÞ4 R
PðR  R1 jn,XR ¼ xR  1, priorÞ4 R
Here R and R are the smallest acceptable posterior probabilities to recommend further research or recommend
no further research. xRC is then the smallest number of responses required to declare the treatment is eﬀective given
n patients are evaluable.
This approach can be extended to multiple endpoints provided there is to be no trade-oﬀ between the endpoints
at the ﬁnal analysis.
6 Bayesian approaches
6.1 Bayesian probabilistic properties approach
This approach deﬁnes a series of stopping rules based directly on the Bayesian posterior probabilistic
properties (PðT  T0 jn, xT, priorÞ, PðT  T1 jn, xT, priorÞ, PðR  R0 jn, xR, priorÞ and PðR  R1 jn, xR,
priorÞ both at interim and at the end of the trial. Posterior probabilities are easy to interpret in the context of
the original problem. Thresholds are set for each posterior probability. The trial stops when the probability
exceeds one of the thresholds. If the trial continues to the ﬁnal analysis, then further research is
only recommended if the threshold is exceeded. A trial can use one or more of the following decision rules to
generate a suitable design:
(i) If PðT4 T1 jn, xT, priorÞ4 T stop for toxicity
(ii) If PðR5 R1 jn, xR, priorÞ4 R stop for futility
(iii) If PðR4 R0 jn, xR, priorÞ4 R and if PðT5 T1 jn,xT, priorÞ4 T stop for eﬃcacy and no toxicity
These decision rules can be used at both interim and ﬁnal analysis. The posterior probability thresholds T,
R, R and T need not be constant across each analysis and may vary with the current number of patients
recruited.
6.2 Bayesian posterior predictive probability approach
Herson14 ﬁrst proposed the use of Bayesian predictive probability to make decisions about early termination
of clinical trials. The rules for recommending further research at the conclusion of the trial are computed
in the same way as for the probabilistic approach above. At an interim analysis with ni patients, the
current posterior distribution is known and hence the posterior predictive distribution can be obtained.
The probability of a successful trial is then the probability that the posterior predictive distribution for n ni
patients will achieve at least the threshold for recommending further research at the conclusion of the trial,
when ni patients have data and n is the maximum number of patients to recruit. The trial will stop for
futility if the probability of a successful trial is suﬃciently low and for eﬃcacy if it is suﬃciently high. If it is
neither high nor low, then the evidence is inconclusive and the trial continues to recruit patients.
This approach is easily extended to multiple endpoints. Each endpoint can have a decision rule. All of the
endpoints must be suﬃciently likely to attain at least the critical value for the trial to stop early for success. It is
also possible, if desired, to stop early for futility if the probability of hitting just one of the endpoints is particularly
low. This provides additional degrees of freedom to the design and is useful if one endpoint (such as toxicity) is of
greater concern to investigators during early stages of the trial.
The thresholds can then be adapted to generate a trial with the desired properties. A trial can use one or more of
the following decision rules to generate a suitable design:
(i) If PðXTpredictive4 xTc  xTi jni, xTi , priorÞ4 T at interim, then stop for toxicity
(ii) If PðXRpredictive5 xRc  xRi jni, xRi , priorÞ4 R at interim, then stop for futility
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(iii) If PððXTpredictive4 xTc  xTi Þ [ ðXRpredictive5 xRc  xRi Þ j ni, xTi , xRi , priorÞ4  at interim, then stop for a
combination of poor treatment and/or high toxicity
(iv) If PððXTpredictive  xTc  xTi Þ \ ðXRpredictive  xRc  xRi Þ j ni, xTi , xRi , priorÞ4 Þ at interim, then stop for eﬃcacy
(v) Recommend further research at ﬁnal analysis if PðR4 R0 jn, xR, priorÞ4 R and PðT5 T1 jn, xT ,
priorÞ4 T
where XTpredictive is the posterior predictive distribution for n ni patients and xTc is the largest xT which
satisﬁes PðT5 T1 jn, xT, priorÞ4 T at the end of the trial. Similarly where XRpredictive is the posterior predictive
distribution for n ni patients and xRc is the smallest xR which satisﬁes PðR4 R0 jn, xR, priorÞ4 R at the end of
the trial.
6.3 Bayesian decision theory approach
Bayesian decision theory is based on minimising the expected loss of each decision and is a good method for
comparing risks and rewards for diﬀerent strategies and decisions. Berry and Ho15 proposed using Bayesian
decision theory within a clinical trial setting to make decisions during the trial, building on the work of Raiﬀa
and Schlaifer16 and DeGroot.17 Berry compared this approach to traditional sequential analysis approaches. As a
decision has to be made at interim analysis, it is appropriate to apply Bayesian decision theory to choose between
the options.
There are three possible outcomes at each analysis of a trial. Each outcome has costs and beneﬁts. For example,
stopping for futility or toxicity is costly if the drug actually works and has an acceptable toxicity proﬁle.
These costs and beneﬁts are deﬁned mathematically in a loss function. At the planned analysis, the expected
cost for each decision is calculated by computing the expected loss for each decision based on the posterior
distribution. The decision with the smallest expected loss is the course of action with the best risk/reward
trade-oﬀ. Continuing the trial will increase the amount of information, but has intrinsic cost if the drug is toxic
or does not work, as well as the monetary cost of running the trial.
Chen and Smith12 extended this methodology in a phase II setting with two endpoints. They discussed the use
of a two-dimensional region: if the true response-toxicity (R, T) pair fell within the acceptable region, then further
research could be recommended. The three loss functions relate the probability of being within the region (eﬃcacy
and no toxicity), the probability of being outside the region (futility and/or toxicity) and the value of collecting
additional information traded oﬀ against the cost of continuing the trial (continue recruitment). As the region
does not have to be square in (R, T) space, a trade-oﬀ can be applied between response and toxicity.7 Chen and
Smith proposed using an odds ratio for response and toxicity when comparing a treatment with existing treatment
options.
When the maximum number of patients is reached, the model can provide a region of uncertainty in which the
data still recommend further recruitment. Unlike other methods, the framework does not force a decision to be
made on concluding the trial, although it is possible to impose a decision here. In this context, the planned trial is
part of a larger trial, censored at the planned maximum number of patients. In a larger trial context, many more
patients are needed to make a conclusive decision when the (R, T) parameters are borderline between regions.
Under this methodology, the trial can continue if the observed data places the trial in this region of uncertainty
and there is funding available.
This framework has two degrees of freedom. The ﬁrst balances stopping for eﬃcacy and no toxicity against
stopping for futility and/or toxicity (type I vs. type II error). The second balances the cost of collecting information
against the cost of stopping incorrectly. The acceptable region also plays a large part in any frequentist properties
computed for designs based on this methodology.
This method relies on backward induction: the decision at 30 patients relies on the loss for the decision made at
35 patients, whilst the decision made at 35 patients relies on the loss for the decision made at 40 patients. This is
due to the continuous treatment loss function, which relies on the critical values used to make the decision at the
next interim analysis. Figure 1 shows a proposed acceptable region alongside a resulting design. There are a
number of alternatively shaped regions.
7 Programmes
The programmes used to perform the analysis for this paper are available for R from the CRAN packages
repository in the EurosarcBayes package. The package contains all of the methods discussed in this paper.
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It also contains the following methods for single endpoint designs: frequentist single stage, Simons two stage,5
Lan-deMets alpha spending,9 the Bayesian posterior probability approach and the Bayesian posterior likelihood
approach. Independent beta priors are implemented for all of the methods.
8 Motivating example
LINES is a small phase II trial testing the eﬃcacy and toxicity proﬁle of linsitinib in patients with relapsed and/or
refractory Ewing sarcoma (ClinicalTrials.gov registration number: NCT02546544). Linsitinib has been tested in a
number of Phase I–III trials,18–21 but in very few patients with Ewing sarcoma. Toxic interactions are therefore still
a major concern and it is important to stop the trial early for futility or toxicity. As this trial is not geared towards
a phase III trial if it is a success, it would also be pertinent to stop early to accelerate more conclusive research.
It is known that Linsitinib (OSI-906) is highly active in embryonic stem cell lines when tested in high throughput
screens, but not all cell lines were equally sensitive. For this reason the ability to stop for futility is appropriate.
Two patients per million per year present with Ewing sarcoma.22 As the LINES trial is not a ﬁrst line treatment,
the patient pool is smaller, 0.6 per million patients. A multinational study is thus required to get a feasible rate of
recruitment. Five countries will have centres, giving a population pool of around 350 million people and a
potential patient pool of approximately 210 a year. Each country will have one specialist centre and referrals
will be made within that country to the centre. Patients may be referred between countries if there is no
participating centre in their home country. It should be feasible to recruit around 30 patients a year. Allowing
for opening of centres, the recruiting target was set at 40 patients over 18 months of recruitment. This is a small
number of patients, which will constrain possible trial designs.
Within the LINES trial, a response rate of 0.2 (R0 ) is considered unacceptable and a response rate of 0.35 (
R
1 ) is
good. A toxic event rate of 0.1 (T1 ) is considered good, whilst a toxic event rate of 0.3 (
T
0 ) is unacceptable. These
four rates combined to give four scenarios to consider. Operating characteristics can be run for each scenario.
When both endpoints are considered, the case (R, T)¼ (0.35, 0.1) gives the power, whilst the highest false positive
rate for the other three scenarios gives the type I error (alpha). The trial aims to have  ¼ 0:1 and power ¼ 0:8
(type II error of 0.2) for frequentist designs and equivalently Z¼ 0.9 and z¼ 0.9 for Bayesian designs. The ideal
power for a phase II trial is power ¼ 0.9. As there are two endpoints that are assumed to be independent, the
overall power is the product of the power for each endpoint.
The data considered in setting target probabilities for response and toxicity included Phase II trials of agents
that target components of the same growth regulatory insulin-like growth factor (IGF) pathway.23–26 Lisnitinib
was expected to improve on these responses because it targets two rather than one receptor (Insulin receptor and
IGF1 receptor). Moreover, pre-clinical eﬀectiveness of linsitinib in cell lines suggested at least 50% of cell lines
Figure 1. Decision rules for the formal Bayesian decision rule approach. Red: stop the trial for futility. Orange: continue the trial.
Green: stop the trial for efficacy.
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would respond to the agent. There was also considerable data on linsitinib in other cancers,18–21 however these
results do not easily generalise to Ewing’s sarcoma. For this reason we decided against using informative priors in
this case.
To show the full power of the Bayesian methods, we show the eﬀects of both non-informative and informative
priors. For this informative prior, we use a weight of 10 patients and set the mean of the beta prior to 0.3 for the
response and 0.2 for the toxicity endpoints. This corresponds to a Beta(3, 7) for the response endpoint, and a
Beta(2, 8) for the toxicity endpoint.
9 Results
Table 1 details the design characteristics for the possible trial designs using non-informative priors. We report the
least extreme Bayesian posterior probabilities across interim analyses for each design. The Bayesian posterior
probabilities for the frequentist designs are computed in a similar way using the critical values at each analysis and
a non-informative Beta(1, 1) prior for both endpoints.












size H1 Futility Efficacy Toxicity
Toxicity
acceptable
Frequentist single stage 44 0.0895 0.1888 44.00 44.00 0.845 0.948 0.996 0.907
Bryant and Day (optimal) 20,50 0.0965 0.1944 31.01 46.16 0.901 0.929 0.997 0.879
Bryant and Day (minmax) 24,41 0.0977 0.1982 33.19 40.26 0.850 0.938 0.993 0.920
Bayesian posterior probability
(single stage)
44 0.1526 0.1161 44.00 44.00 0.910 0.901 0.996 0.907
Bayesian posterior probability
(two stage)
22, 44 0.1491 0.1689 35.02 34.95 0.910 0.901 0.977 0.907
Bayesian posterior probability
(four stage)
11, 22, 33, 44 0.1261 0.2795 26.02 28.14 0.910 0.901 0.952 0.907
Bayesian posterior probability
(six stage)
10, 17, 24, 30, 37, 44 0.1364 0.2680 24.62 26.46 0.910 0.901 0.967 0.907
Bayesian posterior predictive
probability (two stage)
22, 44 0.1477 0.1286 36.11 40.60 0.910 0.901 0.996 0.907
Bayesian posterior predictive
probability (four stage)
11, 22, 33, 44 0.1426 0.1538 30.92 34.71 0.910 0.901 0.996 0.907
Bayesian posterior predictive
probability (six stage)




11 to 44, continuous 0.1471 0.1959 24.34 25.12 0.910 0.901 0.990 0.907
Bayesian decision theory (four
stage, complete)
11, 22, 33, 44 0.1090 0.2657 24.14 29.16 0.910 0.901 0.996 0.907
Bayesian decision theory (six
stage, complete)
11, 17, 24, 30, 37, 44 0.1149 0.2617 24.08 28.20 0.910 0.901 0.996 0.907
Bayesian decision theory (four
stage, censoreda)
11, 22, 33, 44 0.2585b 0.3700b 27.88 32.30 0.978 0.973 0.996 0.979
Bayesian decision theory (four
stage with censored portion)
11, 22, 33, 44,
55, 66, 77, 88
0.0804 0.1741 32.96 37.22 0.958 0.958 0.996 0.927
Bayesian decision theory (six
stage, censoreda)
11, 17, 24, 30, 37, 44 0.2445c 0.3633c 26.07 30.34 0.976 0.975 0.999 0.976
Bayesian decision theory (six
stage with censored portion)
11, 17, 24, 30, 37,
44, 55, 66, 77, 88
0.0819 0.1896 30.75 34.70 0.958 0.958 0.999 0.927
aTrial with 88 patients, censored after 44 patients, with censored interim analysis at 55, 66, 77 and 88 patients. The larger trial is directly below the
censored trial.
bThe type I error includes inconclusive trials with probability 0.2075 and the type II error includes inconclusive trials with probability 0.2276.
cThe type I error includes inconclusive trials with probability 0.1895 and the type II error includes inconclusive trials with probability 0.2006.
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We need to check whether each frequentist design meets the Bayesian design constraints (posterior
probabilities) and whether each Bayesian design meets the frequentist design constraints (alpha and power).
As the single-stage study design does not have any built-in interim analyses, a trial running this design
would expect to recruit the maximum number of patients. Forty-four patients are required to achieve  ¼ 0:1
and power ¼ 0:8. Most of the power is spent on the response endpoint, as it is more expensive than the toxicity
endpoint. The standard power value for single-endpoint phase II trials is 0.9, which gives a sample size of 61
patients. The Bayesian futility endpoint, which is the posterior probability that the response is less than a certain
threshold, is not satisﬁed for this design, as the calculated probability is 0.845 and the threshold is 0.9 (Table 1).
Bryant and Day’s6 design allows stopping early for toxicity and futility. The maximum sample sizes for this
design are 50 and 41 in the optimal and minimax designs, respectively. The expected sample sizes are at most
31.0 and 33.2 under one of the three null hypotheses. This approach does not incorporate stopping early for
eﬃcacy, which prevents issues when the treatment is showing eﬃcacy whilst there is uncertainty about the rate of
toxicity. The Bayesian futility endpoint is also violated for the minmax design, as the calculated futility probability
is 0.850 and the required threshold is 0.9 (Table 1).
The prior distribution used for the Bayesian designs is a uniform uninformative prior for both response and
toxicity. This prior was also used to compute the Bayesian properties of the frequentist designs. As the prior has
the weight of two patients, the Bayesian approach does not signiﬁcantly gain information over the frequentist
design. As there is also a cost to stopping at interim analyses (spending a and power), many of these designs have a
higher type I and type II error.
The Bayesian single-stage design contains the same number of patients as the frequentist design. The
toxicity endpoint is much easier to satisfy in the Bayesian paradigm than the response endpoint. As a single-
endpoint trial, the toxicity endpoint only requires 15 patients, whereas the response endpoint requires 44 patients.
The single-stage Bayesian design and the single-stage frequentist design require the same sample size. However
they require a diﬀerent number of responders to report success. As a consequence of this, the frequentist design
does not satisfy the Bayesian design constraints (posterior probabilities), and the Bayesian design does not satisfy
the frequentist design constraints (alpha and power). The power is shared between the endpoints in the frequentist
design, giving the response endpoint a larger share because it is more costly to achieve. In contrast, each endpoint
is checked independently against R and R for response and T and T for toxicity in the Bayesian design.
The frequentist and Bayesian speciﬁcations for the problem diﬀer from one another. This is true for all the
designs presented.
The posterior probability and posterior predictive probability designs show that increasing the number of
interim analyses increases the type II error and reduces the expected sample size under the frequentist hypotheses.
The posterior predictive probability approach improves on the posterior probability approach by signiﬁcantly
reducing the type I error at the expense of a slightly inﬂated type II error and similar expected sample sizes.
There are two proposed implementations of the Bayesian decision theory method.12 The ﬁrst is a closed
trial design with all decisions made at 44 patients. The second treats the trial as part of a larger trial and
censors the second half of the trial. Interim analyses are conducted after 55, 66, 77 and 88 patients have been
recruited. There is a region of uncertainty between recommending further research and stopping research at
44 patients. Table 1 shows both versions of the trial and includes the uncertainty in the type I and II errors
with a note on the probability of recommending continuing the trial.
Figure 1 shows the decisions that should be made for the censored six-stage Bayesian decision theory trial.
The trial only continues if the (R, T) pair is within the orange regions of the graph. The trial will stop for futility
or toxicity if the (R, T) pair is within the red region and will stop for eﬃcacy if within the green region. Graphs
like Figure 1 can be produced for all of the designs mentioned here. For the posterior probability designs, the
regions are square with no trade-oﬀ between response and toxicity.
The complete trial version has similar properties to the Bayesian posterior probability approach. The censored
version censors about 20% of the trial under the frequentist null and alternative hypotheses. The uncensored trial
has much smaller type I errors than the other trials. The uncensored trials need very few expected patients,
recruiting 5.12 and 4.68 for the four- and six-stage trials, respectively.
Table 2 presents the same methods using the informative prior. The results follow generally the same pattern as
those generated with the non-informative prior. The information is borrowed by replacing eight patients as the
weight of this prior (ten) is greater than the weight of the non-informative prior (two). The price for adding
this information is a small increase in type I and type II errors across all of the methods. If we instead simulated
the prior data as a frequentist, we would simulate 46 patients. The type I and type II errors would then closely
match the results from the non-informative case across all of the methods.
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The ﬁnal design for the LINES trial was a compromise between the methodology discussed here and the design
originally approved by Ethics. The ﬁnal design was based on the posterior probability approach with seven interim
analyses, but was limited to 40 total patients. Without other constraints, we would have recommended the
Bayesian posterior predictive probability approach with six interim analyses.
10 Limitations
Considering the frequentist and Bayesian properties increases the number of properties and the number
of optimisation approaches for a given design increases. All of the designs had a natural trade-oﬀ in
frequentist properties between type I error, type II error and expected sample size under the null and
alternative hypotheses.
In the Bayesian paradigm, the success of the trial could have been deﬁned around similar regions used in the
Bayesian decision theory approach. The proposed approach for the Bayesian posterior and posterior predictive
Table 2. Comparison of approaches for calculating sample size for the LINES trial using informative priors. We use a Beta(3,7) prior

















36 0.1755 0.1451 36 36 0.91 0.901 0.996 0.907
Bayesian posterior probability
(two stage)
18,36 0.1559 0.2257 29.15 27.89 0.91 0.901 0.953 0.907
Bayesian posterior probability
(four stage)
9,18,27,36 0.1497 0.2567 24.29 24.29 0.91 0.901 0.953 0.907
Bayesian posterior probability
(six stage)
9,15,20,25,30,36 0.1508 0.2659 21.32 22.71 0.91 0.901 0.952 0.907
Bayesian posterior likelihood
(two stage)
18,36 0.1662 0.1539 30.81 33.25 0.91 0.901 0.996 0.907
Bayesian posterior likelihood
(four stage)
9,15,20,25,30,36 0.1595 0.1684 25.79 27.02 0.91 0.901 0.996 0.907
Bayesian posterior likelihood
(six stage)






0.1604 0.1921 22.1 22.56 0.91 0.901 0.99 0.907
Bayesian loss function
(four stage, complete)
9,18,27,36 0.1301 0.5727 17.57 25.64 0.922 0.948 0.972 0.992
Bayesian loss function
(six stage, complete)
9,15,20,25,30,36 0.0747 0.4695 16.17 23.54 0.91 0.901 0.972 0.953
Bayesian loss function
(four stage, censoreda)
9,18,27,36 0.2149b 0.6203b 20.26 28.07 0.967 0.975 0.994 0.997
Bayesian loss function




0.0564 0.3192 24.25 34.44 0.947 0.956 0.994 0.954
Bayesian loss function
(six stage, censoreda)
9,15,20,25,30,36 0.2066c 0.6201c 19.36 27.16 0.97 0.975 0.993 0.997




0.0559 0.341 23.18 33.09 0.947 0.956 0.993 0.954
aTrial with 72 patients, censored after 36 patients, with censored interim analysis at 45, 54, 63 and 72 patients. The larger trial is directly below the
censored trial.
bThe type I error includes inconclusive trials with probability 0.2075 and the type II error includes inconclusive trials with probability 0.2026.
cThe type I error includes inconclusive trials with probability 0.1823 and the type II error includes inconclusive trials with probability 0.3209.
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approaches can be compared to square regions that require the posterior probability to be greater than 0.81. This
is a simpliﬁcation: if a region is used, a trade-oﬀ between endpoints is allowed, as in the frequentist designs. This
would more closely match the frequentist design.
This paper does not discuss the use of other non-informative prior distributions (such as the improper prior
Betað0, 0Þ or Jeﬀrey’s prior (Betað12 , 12Þ). It can be argued that the Betað1, 1Þ prior is informative, as it suggests that
one success and one failure are observed before commencing the trial. The improper Betað0, 0Þ prior is closer to a
zero information prior, which is more appropriate from a frequentist perspective. The Betað1, 1Þ prior is also very
optimistic for the response endpoint and very pessimistic for the toxicity endpoint.
11 Conclusions
In this motivating example, a non-informative prior was used. However, should more information be available in
other cases, then the performance of the informative prior should be compared against that of the non-informative
prior, as done here. An eﬃciency gain may be possible in these cases.
No single design approach was optimal under all of the studied conditions. All of the considered designs showed
strengths and weaknesses (Table 3). Any given trial will have a number of possible designs that should be
considered and compared.
Adding an additional endpoint either requires more patients or has a negative impact on the design properties,
regardless of the underlying methodology. Having the extra endpoint causes more error possibilities.
Table 3. Summary of conclusions.
Methodology Advantages Disadvantages
Frequentist Formal control of type I and type
II error
Increased sample size
Bayesian Inclusion of informative prior
information. Particularly
useful when a previous trial
has data that can be used to
inform the prior
Smaller sample size
Continual assessment is possible
Informative priors reduce sample
size, which will increase the
trial type I and type II error
Design
Single stage Trial is simple to design, run and
analyse
Multistage – stop early
for futility
If treatment is futile, the
expected number of patients
exposed is smaller
Small changes in design affect the
trial properties
Multistage – stop early
for efficacy
If treatment if efficacious, the
expected number of patients
required is smaller
accelerating research
Small changes in design affect the
trial properties
Single-stage Frequentist Easy to run and analyse
Bryant and Day two-stage design Frequentist Inclusion of a second endpoint
over Simon’s two-stage design
Type I and type II errors are
higher for the same sample
size
Posterior probability Bayesian Smallest expected sample sizes Highest type I and type II errors
tend to be a non-significant
chance of stopping
prematurely at the first few
interim analysis
Posterior predictive probability Bayesian Good balance between expected
sample size and certainty of
results
Bayes Decision theory Bayesian Easy to extend a trial if the
results are uncertain
Complicated to design
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The Bayesian approaches do not provide value-added changes to frequentist designs unless informative prior
information is incorporated. The Bayesian methods provide signiﬁcant ﬂexibility in trial design by allowing both
multiple interim analyses and multiple endpoints. In contrast, the frequentist methods are capable of multiple
interim analyses or multiple endpoints, but currently no work has been done to accommodate both at the same
time. Trials can be designed in a frequentist or Bayesian setting and compared using both frequentist and Bayesian
properties. This ability to directly compare diﬀerent designs is particularly important from a regulatory point of
view, as fair decisions about a drug’s suitability are required regardless of the trial design or methodology used.
The posterior predictive probability approach is the most balanced Bayesian approach for the LINES trial
considered here. It has a good trade-oﬀ between conﬁdence in the results when stopping early and the expected
number of patients needed to recruit. In contrast, the posterior probability approach tends to recommend stopping
too early. The Bayesian decision theoretic approach would be a suitable design if it were possible to request further
funding and additional patients could be recruited in sensible time frames in the event of borderline results. In the
example discussed, this would occur 20–40% of the time (if between the null and alternative hypotheses) and
would only increase the expected sample size by 4–5 patients under the frequentist null and alternative hypotheses.
It is possible to design a trial in either a frequentist or Bayesian setting, then plan to analyse it in the other
setting. Any given trial design can deﬁne null and alternative hypotheses in the frequentist setting and can deﬁne
Bayesian posterior probabilities. Thus, frequentists can use Bayesian designs, and vice versa. Regardless of the
design approach, the trial will be a series of analyses with critical regions for each analysis.
Without prior information, Bayesian designs do not immediately add value over equivalent frequentist designs.
Deciding between these methodologies should be done in light of key prior information or the intention for further
research. If a future trial following successful results intends to use the prior information from the ﬁrst trial, then
maintaining a Bayesian approach throughout allows the data from the ﬁrst trial to be used. These results would be
discarded in the frequentist setting, unless the trial was formally designed as a phase I/II or phase II/III trial.
The two design approaches will suggest similar sample sizes for the ﬁrst trial. However, under the frequentist
approach, the patients in the ﬁrst trial will be discarded and will have to be replaced with new patients in the
second trial. Under the Bayesian approach, the patients in the ﬁrst trial will not be discarded, resulting in a huge
saving in required sample size for future trials.
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